

D25

WO: D.

762.

XP-002101518

1/1 - (C) WPI / DERWENT  
AN - 82-82639E 25!  
AP - JP870021367 870218  
PR - JP810021367 810218; JP870021367 870218  
TI - Immuno-controlling agent - comprising trans-1-cinnamyl  
4-di:phenyl:methyl:piperazine  
IW - IMMUNO CONTROL AGENT COMPRISE TRANS CINNAMYL DI PHENYL  
METHYL PIPERAZINE  
PA - (EISA ) EISAI CO LTD  
PN - JP57136518 A 820823 DW8239 003pp  
- JP1021813B B 890424 DW8920 000pp  
ORD - 1982-08-23  
IC - A61K31/49 ; C07D295/02  
FS - CPI  
DC - B03  
AB - J57136518 Immuno-controlling agent comprises  
trans-1-cinnamyl-4-diphenyl-methyl piperazine  
(Cinnalazine) of formula (I). Cinnalazine has  
vasospasmolytic action, cerebral vasodilator action,  
blood flow-improving action, cerebral blood  
current-increasing action. It is used to treat e.g.  
vertigo, headache, numbness based on cerebral blood  
flow dyserethesia caused by e.g. cerebral apoplexy  
(encephalorrhgia, cerebral thrombus, cerebral embolus  
etc.), arteriosclerosis, hypertensive cerebral  
circulation insufficiency, caput injury sequella.  
- Cinnalazine has both of immuno-increasing action and  
immuno-inhibiting action and may thus be used for  
treating diseases which may be cured by increasing or  
inhibiting immunoreaction on living bodies, e.g.  
cancer, bacterial infectious diseases, allergic  
diseases, rheumatism and inflammation. When  
administered as immuno-controlling agent, dosage is  
usually 10-300 mg/adult/day orally or parenterally.